AACR 2026 drug development trends for advanced prostate cancer lecture
Source type:
obs· Harvested: 2026-05-04 · Original date: 2026-05-04T04:30:26.370Z Metadata:{"project":"Desktop","type":"discovery","obs_id":65383}
obs/65383 · discovery · 2026-05-04T04:30:26.370Z
AACR 2026 drug development trends for advanced prostate cancer lecture
Research phase for advanced prostate cancer resident lecture gathered four AACR 2026 abstracts representing current drug development frontiers: (1) AR degradation via PROTAC technology with pathway combination (AZD9750+capivasertib targeting AR+AKT), (2) next-generation AR degraders overcoming ARPI resistance (JSB462), (3) alpha-emitting PSMA radioligand mechanistic advances (212Pb showing cell cycle-specific effects), and (4) dual-targeting ADC approaches addressing tumor heterogeneity (PSMA/STEAP1 bispecific). These abstracts map to three therapeutic landscape categories in the source knowledge base: AR degraders, PSMA theranostics, and combination therapy strategies for PTEN-deficient and treatment-resistant disease contexts.
Concepts: [“what-changed”,“pattern”,“how-it-works”]
Facts: [“AB#825 describes AZD9750 AR-PROTAC combined with capivasertib AKT inhibitor achieving 73-100% tumor growth inhibition in PTEN-null models”,“AB#3920 covers JSB462 (Luxdegalutamide) AR degrader effective against wild-type and mutant AR including L702H, H875Y, T878A resistance mutations”,“AB#2714 demonstrates 212Pb-PSMA radioligand therapy induces G1 and G2/M cell cycle arrest with superior DNA damage versus 177Lu-PSMA”,“AB#1888 presents dual-target (PSMA+STEAP1) bispecific ADC with dual payloads (tubulin inhibitor + TOP1 inhibitor) addressing antigen heterogeneity”,“All abstracts reference ongoing phase I/II trials and combination strategies for mCRPC and mHSPC patient populations”]
[← 回 Alfred Brain Hub]